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Abstract
Background: Alzheimer's disease, known to be associated with the gradual loss of 
memory, is characterized by low concentration of acetylcholine in the hippocampus and 
cortex part of the brain. Inhibition of acetylcholinesterase has successfully been used as a 
drug target to treat Alzheimer's disease but drug resistance shown by 
butyrylcholinesterase remains a matter of concern in treating Alzheimer's disease. Apart 
from the many other reasons for Alzheimer's disease, its association with the genesis of 
fibrils by β-amyloid plaques is closely related to the increased activity of 
butyrylcholinesterase. Although few data are available on the inhibition of 
butyrylcholinesterase, studies have shown that that butyrylcholinesterase is a genetically 
validated drug target and its selective inhibition reduces the formation of β-amyloid 
plaques.
Rationale: We previously reported the inhibition of cholinesterases by 2,3-dihydro-1, 5-
benzothiazepines, and considered this class of compounds as promising inhibitors for the 
cure of Alzheimer's disease. One compound from the same series, when substituted with a 
hydroxy group at C-3 in ring A and 2-thienyl moiety as ring B, showed greater activity 
against butyrylcholinesterase than to acetylcholinesterase. To provide insight into the 
binding mode of this compound (Compound A), molecular docking in combination with 
molecular dynamics simulation of 5000 ps in an explicit solvent system was carried out for 
both cholinesterases.
Conclusion: Molecular docking studies revealed that the potential of Compound A to 
inhibit cholinesterases was attributable to the cumulative effects of strong hydrogen 
bonds, cationic-π, π-π interactions and hydrophobic interactions. A comparison of the 
docking results of Compound A against both cholinesterases showed that amino acid 
residues in different sub-sites were engaged to stabilize the docked complex. The relatively 
high affinity of Compound A for butyrylcholinesterase was due to the additional 
hydrophobic interaction between the 2-thiophene moiety of Compound A and Ile69. The 
involvement of one catalytic triad residue (His438) of butyrylcholinesterase with the 3'-
hydroxy group on ring A increases the selectivity of Compound A. C-C bond rotation 
around ring A also stabilizes and enhances the interaction of Compound A with 
butyrylcholinesterase. Furthermore, the classical network of hydrogen bonding 
interactions as formed by the catalytic triad of butyrylcholinesterase is disturbed by 
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Compound A. This study may open a new avenue for structure-based drug design for 
Alzheimer's disease by considering the 3D-pharmacophoric features of the complex 
responsible for discriminating these two closely-related cholinesterases.
Background
Alzheimer's disease (AD) or Senile Dementia of the Alzheimer Type (SDAT) is an irre-
versible but progressive neurodegenerative disorder caused by the loss of neurons and
synapses in the cerebral cortex and certain sub-cortical regions. The main risk factor for
AD is increased age: as people age, the frequency of AD increases. It is estimated that
about 10% of people over 65 years of age and 50% of those over 85 suffer from AD.
Unless novel treatments are developed to reduce the risk, the number of individuals with
AD in the United States is expected to be 14 million by the year 2050 [1].
Cholinesterases (ChEs) are family of enzymes that share extensive sequence homology
( 6 5 % ) .  C h E s  i n  v e r t e b r a t e s  h a v e  b e e n  c l a s s i f i e d  i n t o  t w o  t y p e s ,  a c e t y l c h o l i n e s t e r a s e
(AChE) and butyrylcholinesterase (BChE), on the basis of distinct substrate specificities
and inhibitor sensitivities. AChE (EC 3.1.1.7) is a key component of the cholinergic brain
synapses and neuromuscular junctions. The major biological function of AChE is the
termination of nerve impulse propagation by rapid hydrolysis of the cationic neurotrans-
mitter acetylcholine (ACh). According to the cholinergic hypothesis, memory impair-
ment in SDAT patients results from a deficiency in cholinergic function in the brain [2].
More specifically, low amounts of ACh in the hippocampus and cortex are generally con-
sidered as the cause of AD [3]. Although the exact role of BChE is not yet fully under-
stood, it is reported to be involved in morphogenesis, cytogenesis and tumorigenesis,
regulation of cell proliferation and onset of differentiation during early neuronal devel-
opment, as a scavenger in the detoxification of certain chemicals, and in lipoprotein
(VLD) metabolism [4]. In addition, some neuronal populations show exclusively BChE
activity in the human brain [5], such as hydrolysis of ACh at CNS synapses, and replace-
ment of AChE function in Alzheimer's brains renders BChE as a more potent drug target
than AChE [6]. Biological evidence supports the role of BChE in the disruption of cho-
linergic neurotransmission observed in AD [7]. Processing of α-amyloid protein to β-
amyloid peptide is also associated with the AD-related neurofibrillary tangles [6].
The relationship between AD and the formation of β-amyloid plaques further compli-
cates the etiology of the disease. Many scientists believe that AD results from increased
production or accumulation of α-amyloid in the brain, leading to nerve cell death.
Recent research also has revealed that in the brains of AD patients, the level of acetyl-
cholinesterase (AChE) is considerably reduced whereas that of butyrylcholinesterase
(BChE) increases, thus aggravating the toxicity of β-amyloid peptide. Neurofibrillary
tangles and amyloid plaques express AChE and BChE activity in AD [8]. This abnormal
expression has been detected around the amyloid plaques and neurofibrillary tangles in
the brains of AD patients [9]. It has also been reported that AChE and BChE co-localize
within the brain in amyloid plaques to form insoluble β-amyloid fibrils [10].
Hence, the most promising therapeutic strategy for activating central cholinergic func-
tions has been the use of cholinomimetic agents. The function of cholinesterase inhibi-
tors (ChEIs) is to increase the endogenous levels of acetylcholine (ACh) in the brains of
AD patients, eventually increasing cholinergic neurotransmission. It is not surprisingUl-Haq et al. Theoretical Biology and Medical Modelling 2010, 7:22
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that ChEIs have shown better results in the treatment of AD than any other strategy
explored; for example, compounds having a 2,3,8,8a-tetrahydropyrrolo[2,3-b]indole het-
erocyclic system, a characteristic structural motif of alkaloids such as physostigmine and
phenserine, are considered potent ChEIs for use in AD treatment [11]. Both ChEs show a
characteristic cleft intruding into the enzyme surface, containing the catalytic triad and
choline binding sites where ACh is cleaved. There are several structural features that
delineate and differentiate the cleft between AChE and BChE, including numerous aro-
matic regions present in the latter but not in the former. Both ChEs have their active sites
at the base of enzyme cleft of about 20 Å depth. In AChE, the binding of the substrate is
represented by two phenylalanine molecules (Phe295 and Phe297) whose aromatic side
chains protrude into the cleft [12]. In BChE, these two aromatic amino acid residues are
replaced by two smaller amino acid residues, Leu286 and Val288. This structural differ-
ence causes a conformational change that defines a larger space in the deepest area of the
cleft of BChE to allow the fitting of diverse BChEIs. The availability of BChE to catalyze
diverse substrates depends on the difference between the amino acid residues that line
the cleft [13]. Such structural differences allow the medicinal chemist to explore the
region specific for BChE so that a combination therapy can be employed. As a drug tar-
get, it has been observed that BChE inhibition may also be more effective for the treat-
ment of AD and related dementias [14].
It is well established that many life-saving drugs (~30%) act by inhibiting enzymes.
Therefore, the discovery of novel enzyme inhibitors has been an exciting area for phar-
maceutical research leading to many interesting advances in drug development. We
already have reported a number of new inhibitors of ChEs. We have performed in vitro
testing and studied inhibition kinetics and pharmacological profiles combined with in
silico tools, such as molecular docking and 3D-QSAR (CoMFA and CoMSIA) studies
[15-24]. Benzothiazepine derivatives, two seven-membered N and S heterocyclic ring
systems, have been associated with broad spectrum biological activities [25]. Continuing
our ongoing research for new inhibitors of ChEs and in view of their immense pharma-
cological significance, we have recently synthesized a variety of 2,3-dihydro-1, 5- benzo-
thiazepines by a [4+3] annulation of α,β-unsaturated ketones (chalcones) with o-
aminothiophenol [26,27]. Diversity was introduced by substitutions on both rings A and
B that led to the three sets of compounds: unsubstituted ring A (Set 1), 2'-hydroxy sub-
stitution on ring A (Set 2) and 3'-hydroxy substitution on ring A (Set 3). The compounds
from set 1 and set 2 were generally found to be inactive. In contrast, benzothiazepines
from set 3 was found to be more potent than either the unsubstituted or 2'-hydroxyl-sub-
stituted analogs, indicating that the presence of a 3'-hydroxy group on ring A may be
important for inhibiting ChEs. Moreover, a benzothiazepine from the same set of com-
pounds having a 2-thiophene moiety as ring B was found to be the most potent inhibitor
of both AChE and BChE, with IC50 values of 5.9 and 3.97 μM, respectively (named Com-
pound A in this study - Figure 1) [27]. The availability of several co-crystallized struc-
tures for both ChEs with different inhibitors makes it possible to apply a molecular
docking and dynamics simulation protocol to explore the protein-ligand interactions. As
mentioned earlier, the role of BChE in forming β amyloid plaques in AD patients seems
to be more important, so this mechanistic study will help to predict the possible binding
mode of Compound A and its dynamic behavior within the ChE active site. The study
also focuses on the comparison between the inhibitory potentials of Compound A on theUl-Haq et al. Theoretical Biology and Medical Modelling 2010, 7:22
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two ChEs. In future, it may be necessary to explore the development of potential new
anti-BChE drugs for treating AD and related dementias.
Methods
Molecular structures
The three-dimensional (3D) structure of Compound A - (E)-3-(2-(thiophene-2-yl)-2,3-
dihydrobenzo[b][1,4]thiazepin-4-yl)phenol (Figure 1) - was built using SYBYL® software
(version 7.3, TRIPOS, St. Louis, MO) [28]. Subsequently, the overall geometry was opti-
mized by the Powell method [29] using Tripos force field [30]. 1000 iterations were given
with a convergence criterion of 0.05 kcal/molÅ. Charge distributions were calculated by
Gasteiger-Marsilli method [31].
Preparation of receptor
The X-ray crystal co-ordinates of AChE (PDB ID: 1ACL) [32] and BChE (PDB ID: 1P0P)
[33] in the bound state with decamethonium (DECA) and 2-(butyrylsulfanyl)-N,N,N-
trimethylethanaminium (BCh), respectively, were retrieved from the Protein Data Bank
(PDB) [34]. Since both ChEs have their crystal structures in a state that represents the
Figure 1 3D View. Energy-minimized three dimensional (3D) structure and molecular surface representation 
of A) symbolic compound from set 3 and B) Compound A; R1 = 2-thiophene moiety.Ul-Haq et al. Theoretical Biology and Medical Modelling 2010, 7:22
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pharmacological target for the development of new drugs to cure AD, these two PDBs
were selected for modeling studies. All the heteroatoms including water molecules,
bound ligands and any co-crystallized solvent were removed from the PDB file of both
ChEs. It is well known that PDB files often have poor or missing assignments of explicit
hydrogens, and the PDB file format cannot accommodate bond order information.
Therefore, proper bonds, bond orders, hybridization and charges were assigned using
the Molegro Virtual Docker (MVD - 2008, 3.2.0) [35]. Explicit hydrogens were created
and their hydrogen bonding types were also determined by MVD. The potential binding
sites of both ChE receptors were calculated using the built-in cavity detection algorithm
implemented in MVD. The search space of the simulation exploited in the docking stud-
ies was defined as a subset region of 15.0 Å around the active site cleft.
Molecular docking
Mvds docking search algorithms and scoring functions
Ligand docking studies were performed by MVD, which has recently been introduced
and gained attention among medicinal chemists. MVD is a fast and flexible docking pro-
gram that gives the most likely conformation of ligand binding to a macromolecule.
MolDock software is based on a new heuristic search algorithm that combines differen-
tial evolution with a cavity prediction algorithm [36]. It has an interactive optimization
technique inspired by Darwinian Evolution Theory (Evolutionary Algorithms - EA), in
which a population of individuals is exposed to competitive selection that weeds out
poor solutions. Recombination and mutation are used to generate new solutions. The
scoring function of MolDock is based on the Piecewise Linear Potential (PLP), which is a
simplified potential whose parameters are fit to protein-ligand structures and a binding
data scoring function [37,38] that is further extended in GEMDOCK (Generic Evolu-
tionary Method for molecular DOCK) [39] with a new hydrogen bonding term and
charge schemes.
EPLP uses two different sets of parameters: one for approximating the steric (van der
Waals) term between atoms, and the other for stronger potential for hydrogen bonds.
Moreover, a re-ranking procedure was applied to obtain the highest ranked poses to
increase the docking accuracy further. On average, 10 docking runs were made to obtain
high docking accuracy. MolDock automatically identifies potential binding sites (cavi-
ties) using a flexible cavity detection algorithm, as there is no dependence on the orienta-
tion of the target molecule, so an arbitrary number of directions may be used. The fitness
of a candidate solution is derived from the docking scoring function, Escore and is defined
by the following energy terms:
where Einter is the ligand-protein interaction energy:
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The summation runs over all heavy atoms in the ligand and all heavy atoms in the pro-
tein, including any cofactor atoms and water molecule atoms that might be present. The
second term describes the electrostatic interactions between charged atoms.
Eintra is the internal energy of the ligand:
The double summation is between all atom pairs in the ligand, excluding atom pairs
that are connected by two bonds or less. The second term is a torsional energy term,
parameterized according to the hybridization types of the bonded atoms, while θ is the
torsional angle of the bond. The last term, Eclash, assigns a penalty of 1,000 if the distance
between two atoms (more than two bonds apart) is less than 2.0 Å. Thus, the Eclash term
penalizes non-feasible ligand conformations.
MVD has two docking search algorithms; MolDock Optimizer and MolDock SE (Sim-
plex Evolution). The default search algorithm used in MVD is the MolDock Optimizer
[40,41], which is based on an evolutionary algorithm. From MVD version 1.5, an alterna-
tive heuristic search algorithm named MolDock SE (simplex evolution) is also imple-
mented. MolDock SE performs better on some complexes where the standard MolDock
algorithm fails. Likewise, the two scoring functions, the MolDock Score and its gird-
based version, MolDock Score [GRID] [37-39], are used for evaluating docking solu-
tions. However, exhaustive docking calculations were done using both search algorithms
along with both scoring functions. The five best docking solutions were returned after
each docking run. Hence, for Compound A, a total of 20 scores were generated for each
PDB; however, only the results of the selected docking protocol are mentioned (see
Results and Discussion). The following optimization parameters were used for individual
search algorithm and scoring function.
Parameters for docking search algorithms
a) MolDock Optimizer: In MVD, selected parameters were used for the guided differ-
ential evolution algorithm: number of runs = 10 (by checking constrain poses to cavity
option), population size = 50, maximum iterations = 2000, crossover rate = 0.9, and scal-
ing factor = 0.5. A variance-based termination scheme was selected rather than root
mean square deviation (RMSD). To ensure the most suitable binding mode in the bind-
ing cavity, pose clustering was employed, which led to multiple binding modes.
b) MolDock SE: For pose generation, 1500 maximum iterations were used by selecting
a population size of 50 and were built incrementally from their rigid root point. The pose
generator tests a number of different torsion angles, rotations and translations, evaluates
the affected part of the molecule and chooses the value resulting in the lowest energy
contribution. The poses generated were added to the population if the energy value was
below the 100.0 threshold. At each step, at least 10 min torsions/translations/rotations
were tested and the one giving the lowest energy was chosen. If the energy was found to
be positive (owing to a clash or an unfavorable electrostatic interaction), then an addi-
tional 10 max positions were tested. If it is not possible to construct a component which
EE
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does not clash, the 10 max tries number is lowered to the 10 quick try values. The Sim-
plex Evolution parameters were set at 300 steps with neighbor distance factor of 1.0.
Parameters for scoring functions
a) MolDock Score: The ignore-distant-atoms option was used to ignore atoms far away
from the binding site. Additionally, hydrogen bond directionality was set to check
whether hydrogen bonding between potential donors and acceptors can occur. The
binding site on the protein was defined as extending in X, Y and Z directions around the
selected cavity with a radius of 15 Å.
b) MolDock Score [GRID]: The MolDock Score [Grid] is identical to the MolDock
Score except that hydrogen bond directionality is not taken into account. The grid-based
scoring function provides a 4-5 times speed-up by precalculating potential-energy values
on an evenly spaced cubic grid. (Hydrogen bonding is determined solely on distance and
hydrogen bonding capabilities). The energy potential is evaluated by using tri-linear
interpolation between relevant grid points. The rest of the terms in the MolDock Score
[Grid] version (i.e., internal ligand energy contributions and constraint penalties) are
identical to the standard version of the scoring function. A grid resolution of 0.80 Å was
set to initiate the docking process.
Side chain flexibility
To account for side chain flexibility during docking in MVD, two possibilities are given:
(i) flexible docking by softening potentials and (ii) indicating flexible amino acid residues
during docking. The latter option was chosen for 1ACL. Trp84 and Trp279 were selected
to be kept flexible during docking simulation. The repositioning of the selected side
chains and minimization of ligand were performed using the standard non-softened
potentials. Default potentials for Trp84 and Trp279 side chains were maintained [Toler-
ance = 0.9 Å, Strength = 1.0 Å, Torsional angles = 2 (each), Max T = 23.03 for Trp84 and
32.22 for Trp279, and Mean T = 16.962 for Trp84 and 19.214 for Trp279). Maximum
2000 minimization cycles (for flexible residues and ligand) along with the maximum
2000 global minimization steps were run as post-docking minimization steps using the
Nelder-Mead simplex algorithm [42]. After docking of compound A into the binding
pocket, the selected flexible side chains were minimized with respect to the predicted
pose. After repositioning of the side chains, the ligand was subjected to further energy
minimization.
The resulting docked orientations within a root-mean square deviation of 1.5 Å were
clustered together. All other parameters were maintained at their default settings and the
interaction mode of each pose in the active site of the receptor was determined.
Re-docking of co-crystallized ligands
In order to develop the docking methodology, we first attempted to demonstrate that
bound conformations could be reproduced in silico. For this purpose, DECA and BCh
from the complexes 1ACL and 1P0P, respectively, were re-docked using the template
docking feature implemented in MVD. The fitness evaluation of each re-dcoked pose
was evaluated by considering the RMSDs values, docking scores and similarity scores.
The selected re-docked pose was further evaluated by its interactions and energetic anal-
ysis to investigate the efficiency of the docking search algorithm and scoring function by
comparing its values with the bound conformation.
Molecular dynamics simulation
MD simulations of both ChEs with the docked ligand were conducted in an explicit sol-
vent system using AMBER 9.0 package [43]. AMBER03 force field parameters were usedUl-Haq et al. Theoretical Biology and Medical Modelling 2010, 7:22
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to establish the potentials of proteins, and generalized AMBER force field (GAFF)
parameters were used to establish the potentials of the inhibitor. To ensure the electro-
neutrality of both complexes, seven and six sodium ions were added to the AChE and
BChE systems, respectively, with subsequent solvation by TIP3P rectangular box around
the solute unit. Both boxes resulted in a system of dimensions 91.759 × 89.185 × 87.051
Å3 containing 6693 water molecules in AChE, and 86.344 × 85.476 × 100.642 Å3 contain-
ing 7477 water molecules in BChE. Xleap was used to create the rectangular solvation
box. The solvated protein-inhibitor complex system was subjected to comprehensive
energy minimization before MD simulation. For this purpose, first restrain minimization
of water molecules was done while holding the solute fixed (5000 steps using the steepest
descent algorithm followed by 5000 steps of conjugate gradient minimizations of the
whole system). This step was done to remove steric conflicts between protein-inhibitor
complex and water molecules and to relax the entire system. An unrestrained minimiza-
tion was then carried out using the same procedure as for restrained minimization. Bond
lengths involving hydrogen atoms were constrained using SHAKE algorithm [44] with
harmonic restraints of 25 kcal/molÅ. Both simulated systems were subsequently sub-
jected to a gradual temperature increase from 0 to 300 K over 20 ps, and then equili-
brated for 100 ps at 300 K followed by production runs of 5000 ps. Constant temperature
(298 K) and constant pressure (1 atmosphere) were controlled by the Berendsen cou-
pling algorithm [45] with a time constant for heat-bath coupling of 0.2 ps. The dielectric
constant and cut-off distance were set to 1.0 and 10.0 Å, respectively. Long-range elec-
trostatic calculations were carried out by particle mesh Ewald method [46]. The resulting
trajectories were analyzed by PTRAJ module of AMBER package and VMD [47].
Hardware
Docking studies were carried out on a single Intel® Xeon® Quad™ core processor running
under LINUX OS equipped with a single user license of MVD. The molecular dynamics
simulation studies were calculated using the MPI SANDER module of AMBER installed
on cluster computing facility at PCMD, ICCBS, University of Karachi, consisting of 10
nodes.
Results and discussion
Selection of docking protocol
The selection of a valid docking protocol mainly focuses on the similarity of all re-
docked poses to the crystallographically identified bound orientations. As a primary
analysis measure, each docking protocol returned multiple docking poses and a symme-
try-corrected RMSD was computed for all poses.
The chemical properties of the bound ligands that were utilized for re-docking have 18
steric centers (grey), 2 hydrogen bond acceptors (green) and 2 positive charges (blue) in
DECA and 12 steric centers (grey), 2 hydrogen bond acceptors (green) and 1 positive
charge (blue) in BCh (Figure 2). By using two search algorithms in conjunction with two
scoring functions per 5 poses returned, 40 RMSD values (20 for each co-crystallized
ligand) were obtained. An additional scoring function known as ligand evaluator was
also employed, which also returned 5 poses per run. Of these, MolDock SE combined
w i t h  M o l D o c k  S c o r e  [ G r i d ]  g a v e  t h e  l o w e s t  R M S D  v a l u e s  f o r  b o t h  c o - c r y s t a l l i z e d
ligands, that is only 0.295 Å and 0.203 Å deviations between the top-ranked poses and
the experimental structures of DECA and BCh, respectively (Table 1). Figure 3 shows the
graphical representation of RMSD values and the best fit re-docked co-ordinates withUl-Haq et al. Theoretical Biology and Medical Modelling 2010, 7:22
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respect to the crystal ligand co-ordinates. A visual inspection of these poses also con-
firms a very good alignment of the experimental and calculated positions. These encour-
aging RMSD values demonstrate MVD as very accurate in reproducing the experimental
binding mode.
Evaluation of selected search algorithm and scoring function
As mentioned earlier, the search algorithm MolDcok SE in combination with the scoring
function MolDock Score [Grid] gives the lowest RMSD values of re-docked poses with
reference to the bound crystal conformations. However, that is not the only criterion for
selecting this docking protocol. Therefore, we applied a more stringent measure to
ensure the selected docking protocol showed lower bias. Energetic analysis and interac-
tions as given by the selected docking protocol of top-ranked poses having least RMSD
values were compared to their respective co-crystallized ligands. In 1ACL, the total pose
energy of the bound DECA was found to be -106.542 kcal/mol (-107.498 kcal/mol for re-
docked pose) with the distal quaternary nitrogen atom having an energy contribution of
-13.259 kcal/mol (-13.436 kcal/mol for re-docked pose). The same nitrogen atom is also
involved in making long-range pair-wise electrostatic interactions [Eelec (r < 4.5 Å)] with
O ε 1 of Glu199 at a value of -2.201 kcal/mol (-2.188 kcal/mol for re-docked pose), hav-
ing a distance of 4.341 Å (4.354 Å for re-docked pose). In the case of 1P0P, the total pose
energy of the bound BCh was found to be -69.687 kcal/mol (-72.859 kcal/mol for re-
docked pose) with the nitrogen atom having an energy contribution of -12.793 kcal/mol
(-12.844 kcal/mol for re-docked pose). The same nitrogen atom is also involved in mak-
ing a long-range pair-wise electrostatic interaction [Eelec (r < 4.5 Å)] with O ε 1 of Glu197
at a value of -2.766 kcal/mol (-2.756 kcal/mol for re-docked pose), having a distance of
3.887 Å (3.879 Å for re-docked pose) (Figure 4). Other docking protocols with higher
RMSD values were also checked by such analysis, but none of them provided similarity
Table 1: RMSD values of re-docked conformations of DECA and BCH in 1ACL and 1P0P, 
respectively.
Search Algorithms Scoring Functions RMSDs Values
PDB IDs
1ACL 1P0P
MolDock SE MolDock Score 0.72 0.282
MolDock Score [Grid] 0.295 0.203
Ligand Evaluator 0.467 0.286
MolDock Optimizer MolDock Score 0.956 0.288
MolDock Score [Grid] 0.855 0.211
Ligand Evaluator 0.820 0.211
Table shows only the best RMSD values of each docking run. Italic fonts indicate the best docking 
protocol (See also Figure 3)Ul-Haq et al. Theoretical Biology and Medical Modelling 2010, 7:22
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to these parameters (results not shown). Therefore, it was decided to apply this docking
protocol to Compound A and to obtain the best model. The results of the same docking
protocol were mentioned later (as it also gave the least MolDock Score [Grid]).
Evaluation of poses
After selection and evaluation of the docking protocol, same docking method was
applied to dock Compound A on both ChEs. The docked 3D structures of Compound A
were scored, re-ranked and compared with their respective X-ray crystallographic struc-
tures. An interesting observation was that two major clusters of binding poses were
found to occupy two separate but overlapping regions.
Apart from minor differences, a major diversity in the ligand-AChE complexes was the
variation in the positioning of the side chain of Phe330. The divergence in the orienta-
tion of the aromatic ring of Phe330 must clearly be taken into account in designing anti-
cholinesterse drugs. It has been found that Phe330 engages in cation interactions
Figure 2 Chemical featurers used for MVD re-docking protocol. The chemical properties of bound ligands 
are shown A) DECA, Grey; Steric centers, Green; Hydrogen-bond acceptors, Blue; Positive charges and B) BCH, 
Grey, Steric centers, Green; Hydrogen-bond acceptors, Blue; Positive charges.Ul-Haq et al. Theoretical Biology and Medical Modelling 2010, 7:22
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Page 11 of 26
Figure 3 Graphical representations of RMSD values of top-ranked re-docked poses and superimposi-
tion of selected conformations. Re-docked poses of A) DECA and B) BCH in blue as compared to their bound 
crystallographic conformations in red (See also Table 1).Ul-Haq et al. Theoretical Biology and Medical Modelling 2010, 7:22
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through its π electrons. Moreover, its side chain also guards access to the bottom of the
cleft and adopts three major conformations; open, closed, and an intermediate access
position [48]. For cleft-spanning ligands such as DECA, Phe330 assumes an open access
position in which the side chain is shifted 3.5 Å towards the exterior and parallel to the
DECA, resulting in a wider space than 1W6R (Torpedo calcifornica AChE complexed
with galanthamine). This orientation is considered not only safer for hindrance-free
entry to the ligand but also suitable to observe its experimental rationale as low activity.
Figure 4 Evaluation of selected docking protocol. Atoms of bound and re-docked conformations are 
scaled according to their energy contributions. The green line denotes the electrostatic bond A) DECA - 4.341 
Å (4.354 Å for re-docked pose) and B) BCH - 3.887 Å (3.879 Å for re-docked pose).Ul-Haq et al. Theoretical Biology and Medical Modelling 2010, 7:22
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Therefore, the crystal structure of cocrystallized DECA was used to study protein-ligand
interactions in order to control the performance of our docking approach. The active site
is located 20 Å away from the protein surface at the bottom of a deep and narrow cleft
[49]. For BChE, 1P0P was selected since it has the same substrate analog (butyrylcholine
- BCh) as used for biological screening of BChE.
Figure 5 shows five docked conformations of Compound A in the aromatic cleft of
AChE and in the hydrophobic pocket of BChE. Table 2 summarizes the docking results
of Compound A on ChEs. The lowest MolDock scoring function (based on energy) for
all five poses was found during the docking procedure, indicating that the phase space
was sufficiently sampled. Since our main objective is to find the best model for Com-
pound A, pose energies of the docked compound itself along with the analysis of molec-
ular features and protein-ligand interactions, and the MolDock score [Grid], were
selected as filtration criteria to reject other poses. Prior to this, the RMSD matrix was
Table 2: Energetic analysis of docked Compound A on ChEs.
(A) AChE
Poses MolDoc
k Score 
[Grid]
E-Intra 
(vdw)
H-Bond 
(kcal/
mol)
Non 
H-Bond 
(kcal/mol)
Pose 
Energy 
(kcal/
mol)
Re-rank 
Score
Pose 1 -125.374 71.119 -4.192 -4.192 -124.1 -104.41
Pose 2 -122.393 65.184 -5.026 -7.415 -123.899 -97.385
Pose 3 -122.31 75.752 -6.849 -7.294 -121.124 -92.751
Pose 4 -120.076 71.516 -2.5 -2.5 -119.209 -95.735
Pose 5 -120.037 75.257 -2.5 -2.5 -118.721 -92.9156
(B) BChE
Poses MolDoc
k Score 
[Grid]
E-Intra 
(vdw)
H-Bond 
(kcal/
mol)
Non 
H-Bond 
(kcal/mol)
Pose 
Energy 
(kcal/
mol)
Re-rank 
Score
Pose 1 -125.374 71.119 -4.192 -4.192 -124.1 -104.41
Pose 2 -122.393 65.184 -5.026 -7.415 -123.899 -97.385
Pose 3 -122.31 75.752 -6.849 -7.294 -121.124 -92.751
Pose 4 -120.076 71.516 -2.5 -2.5 -119.209 -95.735
Pose 5 -120.037 75.257 -2.5 -2.5 -118.721 -92.9156
Pose 1 for AChE and Pose 2 for BChE are selected as best model for further modeling studies. Selected 
poses are indicated as Italic fontsUl-Haq et al. Theoretical Biology and Medical Modelling 2010, 7:22
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used to quickly inspect internal deviations between the poses themselves. Pairwise
Atom-Atom RMSD (by checking all automorphisms) was taken into account to consider
the inherent symmetries of the molecule when calculating RMSDs (Table 3 and Figure
6). In the case of 1ACL, pose 1 was found to have the lowest RMSDaverage value (3.987 Å)
compared to its counterparts, which showed that the molecular conformation as pos-
sessed by pose 1 is a combination of all co-ordinates that other poses acquired during the
docking run. It is evident from Figure 6 that pose 1 differed from pose 2 and pose 3 by
1.394 Å and 1.473 Å, respectively. Therefore, the contribution of the energy feature may
also be taken into consideration for selecting pose 1 as the best model for further study.
A comparison of the pose energies of conformations 1, 2 and 3 provides a sound justifi-
cation for selecting pose 1 with energy -141.930 kcal/mol (-136.632 kcal/mol for pose 2
and -136.427 kcal/mol for pose 3) as the model for carrying out further modeling steps.
Likewise, pose 2 and pose 4 as well as pose 3 and pose 5 have pair-wise RMSDs ≥ to 1.5
Å, but neither individual pose energies nor MolDock Score [Grid] values allowed these
poses to be selected as the best model. Moreover, hydrogen bonding interaction energy,
MolDock Score [Grid] and re-rank scores provide further confirmation of pose 1 as the
best choice. The same is true for the docked conformations of compound A in BChE.
Pose 2 gives the lowest RMDSaverage value of 3.377 Å with a conformation closely related
to pose 5 (1.018 Å) and pose 1 (2.198 Å). Pose 2 and pose 5 have discrepancies in their 3'-
hydroxyl group positions on ring A and both can be considered as mirror images owing
to C-C bond rotation. Table 2 B shows that pose 1 has the lowest pose energy of all but
its interactions with the neighboring amino acid residues are not strong enough com-
pared to pose 2.
Hence, the possible ligand-enzyme interactions of benzothiazepine are evaluated by
our selected models, providing a deeper insight into the mechanism of their interactions
and thus helping in the design of potent new ChE inhibitors. The interaction mode of the
selected pose within the active sites of ChEs is described below.
Compound A-AChE complex
The active site of AChE is subdivided into several subsites; for example, the esteratic
subsite, also called the catalytic triad (CT, Ser200, His440, Glu327), oxyanion hole (OH,
Gly118, Gly119, Ala201), anionic subsite (AS, Trp84, Tyr121, Glu199, Gly449, Ile444),
acyl binding pocket (ABP, Trp233, Phe288, Phe290, Phe292, Phe330, Phe331) and
peripheral anionic subsite (PAS, Asp72, Tyr121, Ser122, Trp279, Phe331, Tyr334) are
buried at the bottom of a 20 Å deep aromatic cleft [50]. No interaction was observed
with the atoms of the catalytic triad. The O γ of Ser200 is located 4.8 Å, N ε 2 of His440
5.8 Å and O ε 1 of Glu327 10.4 Å away from the 3'-hydroxy group on ring A. However,
the peptidic NH of Gly119 in the oxyanion hole is involved as a donor in hydrogen bond-
ing interaction with this 3'-hydroxy group. Due to this interaction, the π-electrons of the
peptide bond are more delocalized, further weakening the peptide bond, and may disori-
entate the 3D structure of AChE. The hydroxy substituent on ring A also mediates
another hydrogen bonding interaction with the η hydroxy group of Tyr121 of AS. This
hydrogen bond is approximately equivalent in length (3.17 Å) to the previous hydrogen
bond with Gly119 (3.16 Å). Energetically, the hydrogen bonding with Tyr121 is more
favorable (-1.92 kcal/mol) than that with Gly119 (0.79 kcal/mol), as shown in Figure 7.
The geometrical features of the ligand-enzyme complexes were correlated on the basis
of their morphology and amino acid environment in the macromolecular cavity. It wasUl-Haq et al. Theoretical Biology and Medical Modelling 2010, 7:22
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observed that π-π interactions played an important role in stabilizing the complexes.
Nine amino acids - Tyr70, Ser81, Trp84, Tyr121, Glu199, Phe330, Phe331 Tyr334 and
His440 - were found in the active site of AChE. Compound A was found to penetrate the
aromatic cleft through the flexible six-member ring A and its entrance into the aromatic
cleft was supported by π-π interaction with Phe331. The ligand-enzyme interaction is
further strengthened by Tyr334, which forms a π-π interaction with the six-membered
core benzothiazepine moiety (Figure 8) (see also Additional file 1, Figure S1). Further, the
orientation of ring A at the bottom of the cleft was supported by two hydrogen bonds, as
mentioned, with Gly119 and Tyr121.
Compound A-BChE complex
Major differences between BChE and AChE are restricted to those residues that line the
cleft. In the former enzyme, several of the aromatic groups of the latter are substituted by
hydrophobic ones. Phe288 and Phe290 in the acyl-binding pocket (ABP) of AChE are
replaced by Leu286 and Val288, respectively. These substitutions make it possible for the
binding of a bulkier and more hydrophobic substrate moiety in the active site of BChE.
Table 3: Pair-wise Atom-Atom RMSD (Ǻ) (checking all automorphisms) of all 5 poses 
obtained.
(A) AChE
Poses Pose 1 Pose 2 Pose 3 Pose 4 Pose 5 RMSDaverage
Pose 1 1.394 1.473 6.61 6.471 3.987
Pose 2 1.394 6.941 1.473 6.928 4.184
Pose 3 1.473 6.941 6.61 1.51 4.134
Pose 4 6.61 1.473 6.61 6.874 5.392
Pose 5 6.471 6.928 1.51 6.874 5.446
(B) BChE
Poses Pose 1 Pose 2 Pose 3 Pose 4 Pose 5 RMSDaverage
Pose 1 2.198 7.576 5.99 6.144 5.477
Pose 2 2.198 5.995 4.297 1.018 3.377
Pose 3 7.576 5.995 4.456 4.578 5.651
Pose 4 5.99 4.297 4.456 6.205 5.237
Pose 5 6.144 1.018 4.578 6.205 4.486
Automorphisms of selected poses are indicated as italic fonts (See Figure 6 also)Ul-Haq et al. Theoretical Biology and Medical Modelling 2010, 7:22
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In some cases, the conformation of the acyl binding loop (286-288) of BChE is also
changed as compared to the acyl binding loop (288-290) of AChE. The catalytic triad of
BChE, consisting of Ser198, His438 and Glu325, was located within the 10 Å of the
docked ligand. One of the two catalytic triad residues, O γ of Ser198, is located 4.7 Å
away and O ε 1 of Glu325 is located 6.9 Å away from the 3'-hydroxyl group on ring A. On
comparing these distances with the distances in AChE, it is clear that Compound A is
closer to the catalytic triad in BChE. However, greater potency is observed when the 3'-
hydroxyl substituent on ring A makes a hydrogen bond with N ε 2 of His438, the third
catalytic triad residue. The orientation of N ε 2 of His438 at an angle of 108.859º makes it
suitable as a hydrogen bond acceptor at bond length of 3.07 Å. Owing to the robust bond
angle of C γ itself at 119.972º, N ε 2 of His438 forms an energetically favorable environ-
ment for the 3'-hydroxyl substituent on ring A to form a hydrogen bond. The adjacent
Figure 5 Five Predicted binding modes of Compound A. A) 1ACL and B) 1P0P. Rejected poses are repre-
sented as stick in red while selected pose is represented as color by element mode in stick.Ul-Haq et al. Theoretical Biology and Medical Modelling 2010, 7:22
http://www.tbiomed.com/content/7/1/22
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amino acid residue, Glu197 with both its carboxylates O ε 1 and O ε 2, is also involved in
hydrogen bonding interactions with the same hydroxy group on ring A (Figure 9).
The catalytic triad residues of human butyrylcholinesterase (hBChE) are intercon-
nected by hydrogen bonds. This situation is found in one of the alternate conformations
of the catalytic serine in the choline-hBChE complex (PDB ID: 1P0M). The interaction
with Ser198 maintains His438 in the same position as observed in all hBChE crystal
structures to date. In contrast to the trivial hydrogen bonding interactions between cata-
lytic triad, His438 is no more available to Ser198 when Compound A is present. The dis-
ruption of the hydrogen bond between O γ of Ser198 and N ε 2 of His438 does not allow
efficient proton transfer between Ser198, the leaving alcohol product, and the water
molecule that hydrolyzes the acyl-enzyme.
Figure 6 Graphical representation of pair-wise Atom-Atom RMSD (Ǻ) (checking all automorphisms) of 
all 5 poses obtained. A) 1ACL and B) 1P0P.Ul-Haq et al. Theoretical Biology and Medical Modelling 2010, 7:22
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Another important feature of the benzothiazipine-hBChE complex is the participation
of the carboxyl group of Glu197. To catalyze the mechanism of aging process, a water
molecule serves as a relay for Glu197 to stabilize the positive charge on the protonated
His438. Because of its interaction with Glu197, the water molecule is activated. This
water molecule is ideally positioned to catalyze the mechanism of aging [51]. However,
in this study, it was observed that the 3'-hydroxy substituent on ring A engaged both car-
boxylic oxygen atoms of the side chain of Glu197, making it impossible for BChE to cata-
lyze the aging mechanism. The two hydrogen bonded oxygen atoms of Glu197, which
serve as acceptors, differ markedly in their bond lengths and bond energies. The O ε 1
forms a hydrogen bond at bond length of 3.11 Å with energy of -0.02 kcal/mol while O ε
2 makes stronger hydrogen bond of length 2.87 Å at a lower energy value of -2.5 kcal/
mol. Besides this, the flexible ring A of Compound A accounts for its potency against
BChE since the position of ring A in pose 1 is flipped as compared to pose 2 owing to C-
C rotation, making the pose more effective for inhibition (Figure 10). This rotation
around the C-C bond brought the 3'-hydroxy group on ring A close to Glu197 and
His438, thereby reducing the energy difference between the two poses (see Table 2). Fur-
thermore, Trp82 forms a π-π interaction with ring A and the benzothiazipine moiety of
Compound A while Tyr332 forms a π-π interaction only with the benzothiazepine moi-
ety, which helps to stabilize the overall posture of the docked ligand (see also Additional
file 1, Figure S1).
Figure 7 Docked pose of Compound A in AChE. CT (Ser200, His440, Glu327; yellow), OH (Gly118, Gly119, 
Ala201; purple), AS (Trp84, Tyr121, Glu199, Gly449, Ile444; Grey), ABP (Trp233, Phe290, Phe292, Phe330, Phe331; 
Deep pink), PAS (Asp72, Tyr121, Ser122, Trp279, Phe331, Tyr334; Cyan) and Compound A (green) are represent-
ed as stick model. The hydrogen bonding (black dashed lines with bond lengths) by flexible orientation of ring 
A and molecular surface of Compound A shows how well it fits in the deep and narrow aromatic gorge lined 
with aromatic residues. The residues indicated as italic fonts in legend are considered as dual characteristics.Ul-Haq et al. Theoretical Biology and Medical Modelling 2010, 7:22
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The additional stabilizing interactions between BChE and Compound A that make the
BChE more prone to inactivity are hydrophobic interactions. The five-membered 2-thio-
phene moiety plays a deterministic role in the inhibition of BChE by making hydropho-
bic interactions with Ile69 in the peripheral anionic site.
Molecular dynamics simulation of docked complexes
During MD simulations, total energy, potential energy, kinetic energy, density and tem-
perature were monitored to ensure the stability of the complex. The root mean square
deviation (RMSD) values of the backbone atoms of both proteins also give information
about the structural equilibration of the system (Figure 11). In the Compound A-AChE
system, the RMSD increases until the 200th ps and then remains unchanged up to the
2500th ps. Between the 2500th and 4300th ps, the RMSD slightly increases once again but
then decreases immediately to its initial value up to the whole simulation run time. In
the Compound A-BChE system, the RMSD increases until between the 250th-300th ps.
Up to the 2800th ps, the RMSD attains its maximum value but then remains stable until
the end of the simulation. Overall, the Compound A-BChE system shows higher RMSD
values than the Compound A-AChE system owing to the structural changes caused by
Figure 8 Role of aromatic amino acid residues. π-π interactions between the ring A of Compound A and 
aromatic side chains of Tyr334 and Phe331 (chartreuse). Residues are shown within 5.0 Å in the active site of 
AChE.Ul-Haq et al. Theoretical Biology and Medical Modelling 2010, 7:22
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Compound A. However, both systems converge towards stability and acquire equilibra-
tion.
Although the structure of the protein is not distinctively affected by complexation, the
dynamics of the cleft are changed significantly. These dynamics have already been inves-
tigated extensively by MD simulations, suggesting that the high flexibility of the cleft is
necessary for enzyme activity. A comparison of the simulation results of ligand binding
with the two ChEs shows clear differences, which demonstrate that the inhibitory poten-
tial of Compound A differs among ChEs. In the Compound A-AChE complex, the exten-
sion of the cleft is vital for the entrance of Compound A. The distance between the
center of mass of Trp279 and Gly335 was used to define the cleft width, which varied
between 7.350 Å and 13.501 Å, with a mean of about 10.425 ± 0.1 Å. At about 225-250
ps, the increase and then decease in the width of the cleft allows Compound A to be
accommodated in the active site. During the course of the simulation, the width once
Figure 9 Docked pose of Compound A in BChE. CT (Ser198, His438, Glu325; yellow), OH (Gly116, Gly17, 
Ala199; purple), π-π interacting residues (Trp82, Tyr332; chartreuse) and charged residues (Glu197, Asp70; or-
ange red) are shown here around the molecular surface representation of Compound A. The amino acid resi-
dues in grey are substituted in BChE.Ul-Haq et al. Theoretical Biology and Medical Modelling 2010, 7:22
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again increases and the cleft remains extended till the end of the simulation time (Figure
12). This may indicate disorientation in the aromatic cleft of AChE due to hydrogen
bonding with the peptidic NH of Gly119 formed by Compound A.
The hydrogen bonds seemed to be stronger in the Compound A-BChE complex than
in the Compound A-AChE complex. Figure 13 shows the change in hydrogen bonding
distance between the hydrogen bonded atoms. It is noticeable that for approximately half
of the simulation study, O ε 1 atom of Glu197 holds the substituent on ring A very
strongly. As Compound A fits much better in the active site, it causes a constraint on the
3'-hydroxy group of ring A, decreasing the strength of the hydrogen bond for a very
short time (500-625 ps) and allowing it to hydrogen bond with another atom (Glu197 O ε
2). Both these Glu197 carboxylate oxygens assist in the correct positioning of Compound
A.
The hydrogen bond network interconnecting the residues important for substrate
binding and catalysis is highly persistent. The stabilization of this network results from a
mixture of electrostatic and solvent ordering effects. Another important aspect of the
inhibitory potential of Compound A for BChE shown in this study is the breakage of the
hydrogen bonding pattern in the catalytic triad normally observed in BChE. This molec-
Figure 10 Selection of best pose. Two top poses of Compound A are superimposed to justify the selection 
of correct posture that makes appropriate interactions with BChE. The rotation around C-C bond makes ring A 
more prone towards hydrogen bonding (see Results and Discussion).Ul-Haq et al. Theoretical Biology and Medical Modelling 2010, 7:22
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ular dynamics simulation study illustrates that the O ε 2 atom of Glu197 makes a hydro-
gen bond with the ligand; the N ε 2 atom of His438 is also caught up in hydrogen
bonding to the same atom of the ligand, resulting in the cleavage of the hydrogen bond-
ing interaction between His438 and Ser198 (Figure 14). This situation makes complex of
the catalytic triad which is susceptible for the natural substrate. In other words, the
enzyme is unable to catalyze its natural substrate to product.
The greater flexibility of the outer residues is well illustrated by that of the conserved
Asp70 residue [51]. The Asp70 carboxylate oxygens constantly break and form hydrogen
bond contacts with the nearby hydroxy groups of Ser72 and Tyr332, and meanwhile,
Tyr332 engages itself in a cation-π interaction with the 2-thiophene ring of Compound
A. A cation-π interaction is also formed by the ligand and Phe288 of AChE, but the dis-
tance between these two rings is so large that this interaction is negligible.
Conclusion
Current knowledge of the binding modes and the molecular interactions of the two neu-
ronal Compound A-ChE complexes allow us to design and synthesize compounds pos-
sessing either AChE-BChE selectivity, well balanced AChE-BChE specificity or high
selectivity for BChE only. The last option is more important since the content of BChE in
the brain increases with age, whereas the activity of AChE declines. BChE may, there-
fore, play a more prominent role in ACh hydrolysis in the aging brain. The presence of
BChE in the amyloid plaques and neurofibrillary tangles of AD remains an intriguing
observation. It seems reasonable to assume that this enzyme is a glial product and that
its location in the plaques and tangles may result from the overall inflammatory pro-
cesses relating to AD.
Herein, we have reported a comparative study of the inhibition of ChEs by Compound
A using molecular docking and molecular dynamics simulation techniques. The objec-
Figure 11 RMSD plot. RMSD of the backbone atoms (Cα, N, C) of 1ACL complexed with Compound A with 
respect to the first snapshot as a function of time.Ul-Haq et al. Theoretical Biology and Medical Modelling 2010, 7:22
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tive of this study was to provide a possible relationship between the experimentally
determined IC50 values and the docking interactions of Compound A in the active sites
of ChEs. The docking of Compound A with both ChEs has provided valuable informa-
tion about the nature of the binding interactions of benzothiazepine with these enzymes.
While docking algorithms often successfully predict the bound conformations of a
Figure 12 Movement of aromatic gorge. Width of the aromatic gorge as taken between the center of mass 
of Trp279 and Gly335. The increase and decrease in the width at different time intervals describes the behavior 
of aromatic gorge as distorted by Compound A.
Figure 13 Disturbance of catalytic triad. Involvement of hydrogen bonding interactions during the simula-
tion time.Ul-Haq et al. Theoretical Biology and Medical Modelling 2010, 7:22
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ligand (often down to ≤ 1 Å RMSD of the experimentally determined bound conforma-
tion), most algorithms do not allow for side chain or backbone movement in the binding
pocket, ignoring conformational changes that occur upon ligand binding. It was the goal
of this docking and scoring evaluation to investigate as systematically and exhaustively as
possible the current state of the art in docking and scoring to determine the best possible
binding mode. Our suggested molecular docking protocol accounts for both situations;
that is, it can reproduce a bound complex from the crystal structure considering the side
chain movement. Molecular dynamics simulations illustrate the dynamic behavior of the
cleft and the interactions of Compound A with both ChEs. These results provide a ratio-
nale for the greater inhibitory potential of Compound A, which was found to be primar-
ily based on Gly119, and Glu197 and His438 in the active sites of AChE and BChE,
respectively. In the case of BChE, the hydrogen bonding network interconnecting the
catalytic triad residues (O ε 1 of Glu325, N ε 2 of His438 and O γ of Ser198) is highly
important for substrate binding and catalysis. Our molecular dynamics simulation
revealed a disturbance of this network due to the presence of Compound A. No such
interactions of catalytic triad residues of AChE were observed, consistent with the low
IC50 value of Compound A for this enzyme. On the basis of these in silico studies, it is
possible to predict that benzothiazepine with a 3'-hydroxy group on ring A and a 2-thio-
phene moiety as ring B may be a strong candidate as BChE inhibitor. The fact that ben-
zothiazepine was found to inhibit BChE more strongly than AChE may be rationalized
on the basis of the observation that numerous docked poses of Compound A scored very
highly in terms of hydrogen bonding. The molecular features of Compound A that are
responsible for its specific inhibitory potential against BChE are the 2-thiophene moiety
with an E-total of -40.815 kcal/mol, compared to the same feature in AChE (-38.412
kcal/mol). The 3'-hydroxy substitution on ring A further provides an E-total of -10.028
kcal/mol to the docked conformation in BChE, while the same feature in AChE gives -
7.098 kcal/mol. Additionally, hydrophobic interactions seemed to play a pivotal role in
Figure 14 Breakage of hydrogen bonding interactions between Ser198 and His438.Ul-Haq et al. Theoretical Biology and Medical Modelling 2010, 7:22
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the more specific binding of Compound A to BChE. This study may provide a rational
basis for the structure-based design of benzothiazepine drugs, in combination with a
selected docking protocol, with improved pharmacological properties.
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